ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesisKatarzyna Bogucka, Krishnaraj Rajalingam, Helmut Jonuleit et al.|Cancer Gene Therapy|2020Cited by 15
Correction: ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesisKatarzyna Bogucka, Krishnaraj Rajalingam, Fédérico Marini et al.|Cancer Gene Therapy|2020Cited by 0